Navigation Links
Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
Date:11/5/2007

how that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 28, 2007, June 27, 2007 and September 26, 2007. The Company cautions investors not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.

For further information, please contact Gordon Link, Senior Vice President, Chief Financial Officer, at 303-516-8500.

Contact:

Tapestry Pharmaceuticals, Inc.

Gordon Link

Senior Vice President, Chief Financial Officer

303-516-8500

glink@tapestrypharma.com

Investor:

Lilian Stern

Stern Investor Relations, Inc.

212-362-1200

lilian@sternir.com

Media:

Dana Conti

Schwartz Communications

781-684-0770

tapestry@schwartz-pr.com

Tapestry Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In thou
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Tapestry to Host Conference Call on November 5th to Discuss Third Quarter 2007 Financial Results
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... ... A new host-based therapy for Ebola, anthrax and other ... and its collaborators. The discovery has the potential to speed to market treatments ... by Scientific Reports, an open access research journal from the publishers of Nature. ...
(Date:8/31/2015)... GUELPH, ON , Aug. 31, 2015 /PRNewswire/ - BIOREM ... new orders totalling $5.7 million. The orders are for air emission ... "Of particular note is a large order for a ... our equipment will be replacing a competitor,s system that failed ... see in our engineered solutions," said Derek S. Webb ...
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/53wxp3/israel_biomedical ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Israel Biomedical Sensors market is estimated at $0.19 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/31/2015)... Aug. 31, 2015  US-Australian drug discovery company, ... today confirmed its comprehensive scientific review has identified ... in areas of unmet patient need. Novogen is ... preclinical projects prior to entering into Phase 1 ... Acting Chief Executive Officer, Iain Ross ...
Breaking Biology Technology:Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... pharmaceutical and,medical device company, today announced preliminary ... 30, 2007 and updated its financial,outlook for ... in conjunction with the,release of Boston Scientific ...
... 19 An affiliate of,Phlo Corporation (Pink ... distribution of its vitality product, AQUISS(TM), in ... within Northern California and has,been introduced into ... Springs area. In Northern California, AQUISS(TM) ...
... Radi Medical Systems Sponsors Case Review with Drs. Morton Kern, Nico ... ... Oct. 19 The use,of fractional flow reserve (FFR) for optimizing ... Cardiovascular,Therapeutics symposium, TCT 2007, which will take place Oct. 20-25 in,Washington. ...
Cached Biology Technology:Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 2Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 3Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 4Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 5Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 6Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 7Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 8Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 9Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 10Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 11AQUISS Continues Expansion Into New Territory 2Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007 2
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015   ... focused on improving the user experience and security ... vision technologies, today announced that its TrulySecure™ ... biometric authentication software to be FIDO Certified™. ... TrulySecure for compliance with the FIDO UAF (Universal ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... cycle of ancient flatworms that cause schistosomiasis, Case Western ... to development of the parasites within humans a ... the activator, which turns on rapid growth, is in ... Schistosomiasis, which causes organ damage and failure, ...
... Fla. -- Invasive Burmese python hatchlings from the Florida ... to potentially expand their range through ocean and estuarine ... the Journal of Experimental Marine Biology and Ecology ... conducted by researchers from the U.S. Geological Survey, ...
... Daily doses of a soy germ-based nutritional ... significantly reducing hot flash frequency after 12 weeks ... women published in the peer-reviewed Journal of ... that S-equol, produced from the isoflavone daidzein during ...
Cached Biology News:Crucial gene activator in slow-killing parasite identified 2Crucial gene activator in slow-killing parasite identified 3Salt water alone unlikely to halt Burmese python invasion 2New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 2New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 3New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 4New fermented soy ingredient containing S-equol significantly reduced hot flash frequency 5
...
MultiWash III w/ 12-portStandard Manifold...
... Streptavidin Sepharose High Performance, 5 ml. ... used in HiTrap Streptavidin columns for ... for packing into Tricorn 5/50 GL, ... larger scale purifications are required.Extremely useful ...
...
Biology Products: